Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2022-02-03 | Dr. Brawley brings to the Board scientific expertise and relevant insight into healthcare delivery through his current responsibilities in a leading large academic medical center. |
| 2023-02-03 | Dr. Brawley brings to the Board scientific expertise and relevant insight into healthcare delivery through his current responsibilities in a leading large academic medical center. |
| 2025-01-31 | Dr. Brawley has served as the Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University since 2019. Dr. Brawley served as the Chief Medical and Scientific Officer at the American Cancer Society from 2007 to 2018. |
| Filing Date | Source Excerpt |
|---|---|
| 2022-04-29 | Dr. Brawley has served as a Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University since January 2019. From April 2007 to December 2018, Dr. Brawley served as the Chief Medical and Scientific Officer of the American Cancer Society. From January 2002 to August 2007, Dr. Brawley was director of the Georgia Cancer Center at Grady Memorial Hospital. From April 2001 to December 2018, Dr. Brawley served as Professor of hematology, oncology, medicine and epidemiology at Emory University. Prior to joining Emory University, Dr. Brawley was an assistant director and senior investigator at the National Cancer Institute and an internist and oncologist at the National Institutes of Health Clinical Center and Bethesda Naval Hospital. The Board has concluded that Otis W. Brawley should serve on the Board because he has significant medical and scientific leadership experience. Dr. Brawley’s medical and academic background in oncology and hematology, together with his medical, scientific and public health leadership experience, are expected to assist the Board in its oversight role over our drug discovery and development efforts and to provide the Board with relevant insight into healthcare delivery. In addition, Dr. Brawley has experience serving as a director of other publicly held life sciences companies. Other Public Company Boards: Current Agilent Technologies, Inc. Lyell Immunopharma, Inc. PDS Biotechnology Corporation Past 5 Years None |
| 2023-04-28 | Otis W. Brawley, M.D., Independent Director, Bloomberg Distinguished Professor of Oncology and Epidemiology, Johns Hopkins University, Age: 63, Director Since: 2021, Committees: Science and Technology, 2022 Director Compensation Table: Total $444,968 |
| 2024-04-29 | Otis W. Brawley, M.D. INDEPENDENT DIRECTOR Age: 64 COMMITTEES: Science and Technology DIRECTOR SINCE: 2021 |
Data sourced from SEC filings. Last updated: 2026-02-03